Compare · AZN vs IMNM
AZN vs IMNM
Side-by-side comparison of AstraZeneca PLC (AZN) and Immunome Inc. (IMNM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and IMNM operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 103.6x IMNM ($2.53B).
- Over the past year, AZN is down 10.3% and IMNM is up 106.3% - IMNM leads by 116.7 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 7 for IMNM).
- AZN has more recent analyst coverage (25 ratings vs 13 for IMNM).
- Company
- AstraZeneca PLC
- Immunome Inc.
- Price
- $168.85-0.24%
- $22.30+0.45%
- Market cap
- $261.92B
- $2.53B
- 1M return
- -5.56%
- +24.57%
- 1Y return
- -10.32%
- +106.34%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2020
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 13
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Immunome Inc.
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest IMNM
- CHIEF BUSINESS OFFICER Horn Kinney exercised 1,092 shares at a strike of $12.92 and sold $27,300 worth of shares (1,092 units at $25.00) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors
- Director Barchas Isaac sold $2,412,522 worth of shares (100,000 units at $24.13) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,244,331 worth of shares (55,000 units at $22.62) as part of a pre-agreed trading plan (SEC Form 4)
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Director Barchas Isaac sold $4,393,024 worth of shares (201,050 units at $21.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Medical Officer Lechleider Robert exercised 55,000 shares at a strike of $8.73 and sold $1,091,662 worth of shares (55,000 units at $19.85) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Rosett Max sold $1,093,800 worth of shares (60,000 units at $18.23) as part of a pre-agreed trading plan and exercised 60,000 shares at a strike of $1.05 (SEC Form 4)
- SEC Form 4 filed by Director Swain Sandra M
- SEC Form 4 filed by Director Wagenheim Philip